CytoSorbents to develop broad-spectrum polymer for sepsis treatment
Based on the achievement of pre-determined milestones, the company will receive $1.5m in funding for the first of five years. In addition, DARPA is funding for the development
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
Synthetic Biologics leverages Intrexon’s suite of proprietary technologies for the discovery of fully human mAbs for the treatment of certain infectious diseases not adequately addressed by existing therapies.